根据左心室喷射分数,心力衰竭患者的临床结果,医疗保健资源利用和成本的差异
Juan Carlos López-Azor1, Juan Francisco Delgado2, Jorge Vélez3
1Servicio de Cardiología, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Facultad de Medicina, Universidad Europea, Madrid, Spain.
Revista espanola de cardiologia (English ed.)
|June 18, 2023
概括
左心室喷射分数 (LVEF) 显著影响心力衰竭 (HF) 患者的成本和医疗保健资源利用率. 与保存LVEF (HFpEF) 患者相比,减少LVEF (HFrEF) 的患者承担的成本更高,特别是需要住院的患者.
科学领域:
- 心脏病学 心脏病学
- 卫生经济学 卫生经济学
- 医疗保健管理的管理
背景情况:
- 与心力衰竭 (HF) 患者不同类别的左心室喷射率 (LVEF) 相关的经济负担和资源利用仍然不完全理解.
- 了解这些差异对于优化医疗保健资源配置和患者管理策略至关重要.
研究的目的:
- 为了比较 LVEF 分层的心力衰竭 (HF) 患者的医疗保健资源利用率 (HCRU) 和相关成本.
- 研究减少 (HFrEF),轻度减少 (HFmrEF) 和保存 (HFpEF) 喷射分数对临床结果和经济因素的影响.
主要方法:
- 一项回顾性观察研究分析了1287名在西班牙 (2018年) 初级HF诊断的患者的数据.
- 患者被分为HFrEF,HFmrEF和HFpEF组.
- 在这些LVEF组中比较了一年临床结果,HCRU和成本.
主要成果:
- 与HFmrEF和HFpEF组相比,HFrEF患者的住院率更高,年平均成本明显更高 (ED组4763欧元,医院组6321欧元).
- 对于HFrEF患者来说,增加的成本归因于更频繁的重症监护病房入院和更广泛地利用诊断和治疗干预措施.
- 整体中位成本为ED组1889欧元,医院组5008欧元,在LVEF类别中观察到显著差异 (P <.001).
结论:
- 左心室喷射分数是心力衰竭患者医疗保健成本和资源利用的重要决定因素.
- 高FrEF与医疗保健支出大幅增加有关,特别是对于需要住院治疗的患者,这强调了有针对性的管理策略的必要性.
相关概念视频
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
01:26Heart Failure III: Clinical Manifestations
25
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
25
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17